VERIMATRIX
31.3.2022 17:47:08 CEST | Business Wire | Press release
Regulatory News:
Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Capri Healthcare chose Verimatrix App Shield , part of Verimatrix’s threat defense business line, to gain fast and proven defenses for its TriVice (triage, referral and advice) mobile app.
TriVice streamlines doctor-patient care by managing acute referrals to specialist clinicians routed through its mobile app. The app captures patient demographics, details of the injury/condition and facilitates the sharing of clinical photographs and images. The app triages and enables sending of Advise and Guidance with an aim to reduce avoidable referrals. Additionally, the app enables real-time notification and communication with referring clinicians as well as integration into existing hospital systems. TriVice makes the referral process easier, smoother, seamless and with better documentation. The app’s goal is to advance the digital-first strategy of the National Health Service (NHS), the publicly funded healthcare system in England.
An automated and self-defending cloud-based solution, Verimatrix App Shield provides Capri Healthcare with peace of mind that staff and patient experiences with its TriVice mobile app are protected against numerous nefarious activities. Though a zero-code (no programming required), SaaS approach, App Shield harden apps and helps prevent hacking attacks such as reverse engineering, application repackaging, dynamic modification, man-in-the-middle attacks and much more.
“Capri Healthcare is an organization driven by the vision of turning the NHS digital-first strategy into reality by bringing digital innovation into the working of healthcare providers,” said Krishna Thakur and Valleesh Athreya, founders at Capri Healthcare. “We are dedicated to using technology to improve care, identifying patient conditions earlier, reducing backlog, digitizing processes and eliminating wasteful tasks. We realize that all of that is only possible if we do so by deploying solutions that are secure and trusted by all. Verimatrix answers that need by quickly and cost-effectively adding enterprise-quality threat defense to our TriVice mobile app.”
“At Verimatrix, we are proud to support innovative organizations such as Capri Healthcare that develop, deploy and accelerate the adoption of breakthrough mobile health experiences that strive to make the world a healthier, better place,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “We are especially pleased to work with healthcare innovators like Capri Healthcare, as practitioners and patients alike see privacy and security as a standard expectation, especially as new digital processes are established and adopted. This announcement proves again that Verimatrix’s threat defense solutions are essential for the global healthcare market that is rapidly adopting mobile technologies.”
About Capri Healthcare
Capri Healthcare is an organization driven by the vision of turning the NHS Digital First strategy into reality by bringing digital innovation to healthcare providers. Leading healthcare organizations into the digital era by redesigning and developing patient-centric online systems (web & mobile), Capri Healthcare helps significantly reduce the burden on staff as well as the NHS. The company prides itself in offering a range of technology-driven innovative solutions that drive the healthcare industry’s digital agenda. Visit www.caprihealthcare.co.uk
.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005504/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom